www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

Earnings Release & Call Transcripts

Receive E-mail AlertsE-mail Alert Icon Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!

Earnings Press Releases

Date Title
Toggle Summary Taro Provides Results for the Year Ended March 31, 2021
HAWTHORNE, N.Y. --(BUSINESS WIRE)--May 19, 2021-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2021 . Quarter ended March 31, 2021 Highlights ─ compared to March 31, 2020 Net sales of
Toggle Summary Taro Provides Results for September 30, 2020
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Oct. 28, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2020 . Quarter ended September 30, 2020 Highlights ─ compared to September 30,
Toggle Summary Taro Provides Results for Quarter Ended June 30, 2020
Quarter reflects One-Time Charge for Global Resolution with DOJ HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 29, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today provided unaudited financial results for the quarter ended June 30, 2020 .
Toggle Summary Taro Provides Results for the Year Ended March 31, 2020
HAWTHORNE, N.Y. --(BUSINESS WIRE)--May 19, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2020 . Quarter ended March 31, 2020 Highlights ─ compared to March 31, 2019 Net sales of
Toggle Summary Taro Provides Results for December 31, 2019
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Feb. 3, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2019 . Quarter ended December 31, 2019 Highlights ─ compared to December 31, 2018
Toggle Summary Taro Provides Results for September 30, 2019
Board of Directors Approves $300 Million Share Repurchase Program HAWTHORNE, N.Y. --(BUSINESS WIRE)--Nov. 4, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2019 .
Toggle Summary Taro Provides Results for Quarter Ended June 30, 2019
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Aug. 8, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2019 . Quarter ended June 30, 2019 Highlights - compared to June 30, 2018 Net sales of $161.3
Terms of Use
|
Privacy Statement
|
Safe Harbor Statement